Last updated: September 7, 2026
Methyltestosterone is a mature, low-revenue androgen with no meaningful remaining patent exclusivity, limited commercial availability, and declining clinical relevance. The market is dominated by low-cost alternatives, including testosterone cypionate, testosterone enanthate, transdermal testosterone, and oral testosterone undecanoate. Public sources do not disclose a reliable standalone revenue figure for methyltestosterone, but its commercial profile indicates a small, fragmented generic market rather than a growth product.
What is methyltestosterone and where is it used?
Methyltestosterone is a synthetic orally active androgen derived from testosterone. It is also known as 17-alpha-methyltestosterone. The active ingredient was developed to withstand first-pass hepatic metabolism, allowing oral administration.
Historical FDA-labeled uses have included:
- Testosterone replacement in males with androgen deficiency
- Treatment of delayed puberty in selected male patients
- Palliative treatment of advanced breast cancer in some female patients
- Selected androgen-deficiency conditions under specialist supervision
Methyltestosterone is supplied primarily as oral tablets. Historical strengths include 10 mg and 25 mg. The drug is not interchangeable with injectable testosterone on a milligram-for-milligram basis because route, metabolism, pharmacokinetics, and toxicity differ.
The drug carries clinically important androgenic and hepatic risks. Oral 17-alpha-alkylated androgens, including methyltestosterone, have been associated with cholestatic jaundice, peliosis hepatis, hepatic adenomas, and other liver complications. Product labeling also addresses virilization, lipid changes, edema, prostate-related effects, and cardiovascular or thrombotic concerns associated with androgen therapy [1].
What is the FDA regulatory status of methyltestosterone?
Methyltestosterone has a long-established FDA regulatory history, but its commercial status is weak. Historical branded products included Android-10, Testred, and other methyltestosterone tablet products. Several branded products have been discontinued or are no longer actively marketed.
FDA records distinguish between a product being commercially discontinued and being withdrawn for safety or effectiveness reasons. A discontinued listing alone does not establish that FDA found the drug unsafe or ineffective [2].
The current regulatory picture is characterized by:
| Regulatory factor |
Methyltestosterone status |
| FDA approval history |
Long-standing approval history for oral androgen products |
| Current branded market |
Limited or absent compared with historical availability |
| Generic availability |
Historically available through abbreviated new drug applications and legacy products |
| FDA exclusivity |
No meaningful remaining new-drug exclusivity |
| Controlled-substance status |
Schedule III anabolic steroid under federal law |
| Biosimilar pathway |
Not applicable; methyltestosterone is a small molecule |
| Primary FDA pathway for new generic entrants |
ANDA approval |
| Main regulatory barriers |
Bioequivalence, manufacturing compliance, controlled-substance requirements, labeling, and supply continuity |
Methyltestosterone's Schedule III status adds distribution, recordkeeping, quota, and compliance obligations under the Controlled Substances Act. These requirements can raise operating costs for a product with limited revenue potential [3].
What patents protect methyltestosterone?
No commercially meaningful patent estate protects the original methyltestosterone molecule. The compound is an old active pharmaceutical ingredient, and composition-of-matter protection expired many decades ago.
The relevant intellectual-property position is:
| Patent category |
Current commercial significance |
| Original compound patent |
Expired |
| Basic oral formulation patents |
Expired or commercially irrelevant |
| Historical use patents |
Expired |
| Modern formulation patents |
No widely recognized active estate supporting a branded methyltestosterone franchise |
| Manufacturing patents |
Potentially relevant to a specific process, but not a broad barrier to generic supply |
| Orange Book patent protection |
No meaningful active patent barrier generally associated with methyltestosterone tablets |
The absence of active exclusivity means that a sponsor cannot rely on patent-protected pricing. Any remaining commercial advantage would have to come from manufacturing cost, regulatory status, reliable supply, a niche distribution channel, or a differentiated formulation.
When did methyltestosterone lose exclusivity?
Methyltestosterone lost meaningful exclusivity long before the modern generic pharmaceutical market. Its patent life predates the current Hatch-Waxman framework, and generic competition has been possible for decades.
The commercial consequences are direct:
- No originator-controlled pricing remains.
- Generic entrants do not face a modern compound patent.
- Any approved generic can compete primarily on price and supply.
- Product differentiation requires a new formulation, delivery system, or clinical positioning.
- A new formulation would need its own patent and FDA approval strategy.
The old age of the molecule also limits the value of pursuing new patent claims. A sponsor could potentially patent a specific formulation, dosage regimen, manufacturing process, or delivery system, but broad protection around methyltestosterone itself would be difficult to obtain.
Are there Paragraph IV challenges involving methyltestosterone?
Methyltestosterone is not a significant current Paragraph IV litigation target.
Paragraph IV litigation usually arises when a generic applicant certifies that one or more patents listed for a reference product are invalid, unenforceable, or not infringed. That framework has limited relevance where the reference product has no active patent estate or where listed products are discontinued and commercially insignificant.
For methyltestosterone:
- There is no widely reported active Paragraph IV campaign involving a major branded reference product.
- No material patent dispute is commonly associated with the molecule.
- Any ANDA competition would more likely proceed without a meaningful patent litigation overlay.
- Litigation risk is more likely to involve product liability, manufacturing quality, controlled-substance compliance, or supply contracts than patent infringement.
The absence of Paragraph IV activity reduces legal launch risk but also confirms the lack of a valuable protected market.
What formulations are protected by methyltestosterone patents?
Historical methyltestosterone products were primarily immediate-release oral tablets. Those products do not have a commercially significant active formulation-patent barrier.
Potential areas for future protection could include:
- Modified-release oral tablets
- Sublingual or buccal delivery
- Lower-dose formulations designed to reduce hepatic exposure
- Combination products
- Novel excipient systems
- Long-acting implants or depot formulations
- Transdermal or mucosal delivery platforms
- Formulations intended to improve pharmacokinetic consistency
These approaches would compete with established testosterone delivery systems. A new formulation would face the additional burden of demonstrating a meaningful clinical or pharmacokinetic advantage over inexpensive testosterone products already available.
The main technical weakness of conventional oral methyltestosterone is hepatic exposure. That creates a product-development tradeoff: a sponsor would need to preserve oral convenience while reducing liver toxicity and avoiding excessive androgenic effects.
How strong is the methyltestosterone patent estate?
The patent estate is weak from a commercial perspective.
| Patent-strength factor |
Assessment |
| Molecular protection |
None of practical value |
| Remaining term |
Not commercially relevant |
| Formulation protection |
No broad active estate identified |
| Manufacturing protection |
Potentially narrow and process-specific |
| Litigation leverage |
Low |
| Freedom to operate |
Generally favorable for the active ingredient, subject to process and formulation review |
| Pricing power |
Very low |
| Defensive value |
Minimal |
A company acquiring methyltestosterone rights would be buying regulatory history, manufacturing capability, or distribution access rather than patent exclusivity.
The most valuable intangible asset would likely be a dependable FDA-compliant supply chain. Many older generic drugs experience intermittent shortages because only a small number of manufacturers remain willing to produce them. That type of scarcity can support temporary price increases, but it does not create durable franchise value.
What is the Orange Book status of methyltestosterone?
The Orange Book is relevant for determining reference-listed drugs, therapeutic-equivalence ratings, patent listings, and exclusivity. Methyltestosterone's Orange Book position is consistent with an old generic product:
- Historical methyltestosterone tablet products have been listed through FDA's drug-product databases.
- Any listed patents associated with legacy products are not understood to provide a meaningful current barrier.
- No active new-drug exclusivity supports a premium market position.
- Therapeutic-equivalence designations, where applicable, are product-specific and depend on the approved strength, dosage form, and reference product.
Orange Book status does not guarantee active commercial supply. A product can remain in FDA records even after the manufacturer stops marketing it. The distinction matters because a regulatory listing may preserve a reference-product history without creating a commercially protected market [2].
Which companies are challenging methyltestosterone?
No major current challenger group is associated with methyltestosterone. Competition is diffuse and comes from:
- Generic manufacturers with legacy oral androgen approvals
- Compounding pharmacies, subject to applicable federal and state requirements
- Testosterone replacement products from large pharmaceutical companies
- Injectable testosterone manufacturers
- Transdermal gel and patch manufacturers
- Oral testosterone undecanoate developers and marketers
The principal competitive threat is therapeutic substitution, not direct methyltestosterone patent competition. Physicians can select other testosterone products with better-established dosing options, broader commercial support, and, in some cases, less concern regarding hepatic first-pass exposure.
How does methyltestosterone compare with competing testosterone products?
| Product category |
Route |
Main commercial advantage |
Main limitation versus methyltestosterone |
| Methyltestosterone |
Oral |
Simple administration and low manufacturing complexity |
Hepatic risk and limited modern market support |
| Testosterone cypionate |
Intramuscular |
Low cost and widespread use |
Injection burden and fluctuating levels |
| Testosterone enanthate |
Intramuscular |
Established replacement therapy |
Injection burden |
| Transdermal gel |
Topical |
Avoids oral first-pass metabolism |
Transfer risk, skin absorption variability, higher cost |
| Testosterone patch |
Transdermal |
Nonoral delivery |
Skin reactions and adherence issues |
| Oral testosterone undecanoate |
Oral |
Modern oral replacement option |
Higher cost and product-specific pharmacokinetic requirements |
| Testosterone pellets |
Implantable |
Long dosing interval |
Procedure requirement and difficult reversibility |
Methyltestosterone retains a narrow role where oral administration is preferred and a prescriber accepts its risk profile. It does not have a clear cost or convenience advantage over all alternatives because many testosterone products are generic and widely available.
What is the financial trajectory for methyltestosterone?
Methyltestosterone has a declining or flat financial trajectory rather than a growth trajectory.
A reliable public revenue figure is not available because manufacturers generally report testosterone products in broader portfolios. Public companies do not typically disclose methyltestosterone sales separately from other hormone therapies or generic products.
The economic profile can be summarized as follows:
| Financial driver |
Effect on methyltestosterone |
| Patent expiry |
Removes pricing power |
| Generic competition |
Compresses gross margin |
| Small patient population |
Limits volume |
| Oral administration |
Preserves a niche use case |
| Hepatic safety concerns |
Restricts prescribing |
| Controlled-substance compliance |
Raises operating burden |
| Limited manufacturer base |
Creates possible supply volatility |
| Lack of promotion |
Reduces demand generation |
| Competing testosterone products |
Shifts prescribing away from methyltestosterone |
| New formulation potential |
Offers upside only with substantial development risk |
The product can remain economically viable for a manufacturer with existing hormone manufacturing, established controlled-substance infrastructure, and low incremental production costs. It is less attractive as a standalone investment because the addressable market is narrow and the product has limited ability to sustain premium pricing.
Revenue spikes could occur during shortages or when a competitor exits the market. Those spikes would likely reflect temporary supply constraints rather than durable demand expansion. A manufacturer seeking stable returns would generally prefer a portfolio of testosterone products rather than a single methyltestosterone SKU.
What generic launch scenarios exist for methyltestosterone?
Three launch scenarios are commercially plausible.
Low-price generic entry
A manufacturer launches a standard immediate-release tablet through an ANDA pathway. The product competes on availability and price. This scenario has low legal risk but limited margin potential.
Shortage-driven entry
A manufacturer enters after supply disruption or competitor withdrawal. Pricing may improve temporarily, especially if wholesalers and pharmacies need a substitute source. The opportunity depends on the entrant's ability to maintain uninterrupted production.
Differentiated reformulation
A sponsor develops a modified-release, mucosal, or lower-hepatic-exposure product. This could support new patent protection, but it would require clinical development, FDA review, and evidence of a meaningful benefit over existing testosterone therapies.
The third scenario is the only path to substantial strategic value, but it also carries the highest development and regulatory risk.
What patent litigation and settlement agreements affect methyltestosterone?
No material current patent litigation or settlement agreement is widely associated with methyltestosterone. There is no prominent originator-generic settlement structure comparable with litigation involving high-revenue branded drugs.
The lack of settlement activity reflects the product's economics. A patent dispute is expensive, while the addressable market is too small to justify significant litigation expenditure. Commercial disputes are more likely to concern manufacturing agreements, supply interruptions, quality investigations, or controlled-substance distribution.
What geographic markets are relevant to methyltestosterone?
The United States is the most relevant market for Orange Book, ANDA, and Schedule III analysis. Outside the United States, regulatory treatment varies.
Key geographic differences include:
- Prescription controls differ by country.
- Some jurisdictions may classify methyltestosterone as a controlled anabolic steroid.
- Product availability may depend on legacy national approvals.
- Generic competition can be more fragmented outside the United States.
- Patent terms and regulatory exclusivity may have expired at different times, although the molecule's age makes broad remaining exclusivity unlikely.
- Local manufacturing and import controls can affect supply.
The commercial opportunity is therefore country-specific, but no major geographic market is likely to support an originator-style franchise based solely on methyltestosterone.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are more important than patent barriers.
A commercial manufacturer must manage:
- Active pharmaceutical ingredient sourcing
- Controlled-substance inventory controls
- Content uniformity and dissolution testing
- Stability and packaging requirements
- FDA current good manufacturing practice compliance
- Inspection readiness
- Supplier qualification
- Distribution controls
- Recall and pharmacovigilance procedures
The active ingredient itself is not difficult to protect through patent rights. The harder problem is producing it profitably at small volume while maintaining compliance. This explains why older drugs can experience supply problems despite having no patent barriers.
Key Takeaways
- Methyltestosterone is an old oral androgen with no meaningful remaining compound or market exclusivity.
- Its patent estate is commercially weak, and current Paragraph IV or patent litigation activity is not material.
- FDA regulatory history exists, but branded availability has declined and commercial supply is limited.
- The drug is a Schedule III anabolic steroid, which increases compliance and distribution costs.
- Public companies do not generally report methyltestosterone revenue separately.
- Financial prospects are modest and depend on low-cost manufacturing, reliable supply, and temporary shortage conditions.
- The main competitive threat comes from alternative testosterone delivery systems, not from patented methyltestosterone products.
- A commercially significant opportunity would require a differentiated formulation with a credible safety or pharmacokinetic advantage.
- For investors or licensees, manufacturing capability and distribution access matter more than patent ownership.
FAQs About Methyltestosterone Market Potential
Is methyltestosterone still commercially available?
Availability is limited and varies by country, strength, manufacturer, and pharmacy distribution channel. Historical products remain documented in FDA records even when commercial marketing has stopped.
Does methyltestosterone have an active composition patent?
No commercially meaningful composition patent remains for methyltestosterone. The molecule has been available for generic competition for decades.
Can a generic company launch methyltestosterone without Paragraph IV litigation?
Potentially. The absence of a meaningful active patent estate reduces the likelihood of a Paragraph IV dispute, although an applicant must still satisfy FDA approval, bioequivalence, manufacturing, and controlled-substance requirements.
Is methyltestosterone a biosimilar opportunity?
No. Methyltestosterone is a chemically synthesized small molecule, so the relevant pathway is an ANDA or, for a novel formulation, an NDA. The biosimilar pathway does not apply.
Could a new methyltestosterone formulation command premium pricing?
Only if it demonstrates a material clinical, safety, adherence, or pharmacokinetic advantage. A reformulation could create new intellectual-property rights, but it would face competition from established nonoral and newer oral testosterone products.
References
-
DailyMed. (n.d.). Methyltestosterone tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Drug Enforcement Administration. (n.d.). Controlled substances act: Schedule III anabolic steroids. https://www.deadiversion.usdoj.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Discontinued drug product list. https://www.accessdata.fda.gov/scripts/cder/daf/
